MCM
CTMX icon

Monimus Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Monimus Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-364,306
Closed -$375K – 52
2024
Q4 		$375K Buy
+364,306
New +$392K 0.35% 45

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Monimus Capital Management's CTMX Position: Q1 2025 in Review

Monimus Capital Management sold out of CytomX Therapeutics (CTMX) in Q1 2025, closing a stake of 364,306 shares — an estimated $375K sold.

Monimus Capital Management first reported a position in CTMX in Q4 2024 and held it in 1 quarter. The position peaked at $375K in Q4 2024. 66 funds tracked by Wall St. Rank hold CTMX as of Q1 2025.

  • Monimus Capital Management reported no remaining CytomX Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Monimus Capital Management sold 364,306 CytomX Therapeutics shares in Q1 2025, an estimated $375K.
  • Monimus Capital Management first reported a position in CytomX Therapeutics in Q4 2024 and held it in 1 quarter.
  • Monimus Capital Management's CytomX Therapeutics position peaked at $375K in Q4 2024.
  • 66 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2025.

Based on Monimus Capital Management's 13F filing for Q1 2025, filed 15 May 2025.